Lenalidomide in myeloma.
The standard treatment approach to symptomatic myeloma consists of induction therapy, consolidation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in appropriate patients, maintenance therapy, and salvage therapy. Salvage therapy is of particular importance because not all patients respond to primary therapy, and relapse is virtually universal in responding patients. Newer agents such as thalidomide, bortezomib, and lenalidomide are very active in patients with relapsed or refractory disease. Their use singly and in combination results in excellent cytoreduction including complete remissions in patients relapsing - even after extensive prior therapy. These novel agents have been usually used as salvage therapy in patients relapsing after standard treatment options including transplantation; a setting in which they are thought to improve survival. However, there is an increasing trend to start using them early in the course of the disease; for induction therapy. While early deployment of these agents is certainly associated with high-response rates, evidence that this improves long-term outcome (survival) in patients who subsequently undergo intensive therapy and transplantation is lacking. Toxicity, expense, and possible long-term consequences on the biology of the disease (for example, development of refractory relapse) remain a concern. The most appropriate use of newer agents such as lenalidomide is as salvage therapy of relapsed or refractory disease, and their use as part of induction therapy should be confined to clinical trials until additional data and long-term follow-up are available.
Singhal
Seema
S
The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA. s-singhal@northwestern.edu
Mehta
Jayesh
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Blood. 2001 Jul 15;98(2):492-4
11435324
Ann Oncol. 2006 Dec;17(12):1766-71
16980599
Blood. 2000 Nov 1;96(9):2943-50
11049970
N Engl J Med. 2006 May 11;354(19):2079-80
16687729
Blood. 2002 Jun 15;99(12):4525-30
12036884
Blood. 2006 Nov 15;108(10):3289-94
16873668
N Engl J Med. 2006 May 11;354(19):2079-80
16696148
N Engl J Med. 2003 May 8;348(19):1875-83
12736280
Blood. 2001 Jul 1;98(1):210-6
11418482
N Engl J Med. 1999 Nov 18;341(21):1565-71
10564685
Curr Treat Options Oncol. 2003 Jun;4(3):229-37
12718800
Blood. 2005 Dec 15;106(13):4050-3
16118317
Br J Haematol. 2006 Oct;135(2):158-64
16939489
Lancet. 2006 Mar 11;367(9513):825-31
16530576
Blood. 1999 Jan 1;93(1):55-65
9864146
Arch Dermatol. 2006 Oct;142(10):1298-302
17043184
J Immunol. 1999 Jul 1;163(1):380-6
10384139
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
Blood. 2006 Nov 15;108(10):3458-64
16840727
Bone Marrow Transplant. 2002 Nov;30(10):673-9
12420206
Clin J Am Soc Nephrol. 2006 Nov;1(6):1322-30
17699365
Blood. 2002 Nov 1;100(9):3063-7
12384400
N Engl J Med. 2003 Dec 25;349(26):2495-502
14695409
Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30
10386948
Blood. 1998 Nov 1;92(9):3131-6
9787148
Bone Marrow Transplant. 1998 Nov;22(9):835-43
9827810
Blood. 2002 May 1;99(9):3163-8
11964279
N Engl J Med. 1996 Jul 11;335(2):91-7
8649495
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Hematol J. 2003;4(6):379-98
14671610
Blood. 2005 Dec 1;106(12):3755-9
16105975
Mayo Clin Proc. 2007 Oct;82(10):1179-84
17908524
N Engl J Med. 2006 Mar 9;354(10):1021-30
16525139